• Runmin Li, Ying Li, Bingchen Li, Haiyang Sun, Xinyu Liu, Xin Ge, Yuanxiang Liu, and Jiguo Yang.
• College of Traditional Chinese Medicine, Shandong University of Traditional Chinese Medicine, Jinan.
• Medicine (Baltimore). 2020 Aug 7; 99 (32): e21615e21615.

BackgroundFrom the end of 2019 to the present, coronavirus disease 2019 (COVID-19) has put considerable pressure on the worlds medical system and caused significant mortality and economic losses around the world. In China, the Shufeng Jiedu capsule has been widely used in the treatment of COVID-19, but there is still a lack of evidence-based medical evaluation.MethodsAccording to the retrieval strategies, randomized controlled trials (RCTs) on the Shufeng Jiedu capsule for COVID-19 were obtained from CNKI, WanFang, VIP, PubMed, Embase and Cochrane Library, regardless of publication date, or language. Studies were screened based on inclusion and exclusion criteria, and the Cochrane risk bias assessment tool was used to evaluate the quality of the studies. The meta-analysis was performed using RevMan 5.3 and STATA 14.2 software. Ultimately, the evidentiary grade for the results will be evaluated.ResultsThis study will evaluate the efficacy and safety of the Shufeng Jiedu capsule in the treatment of COVID-19 and provide a more reasonable choice of medication in clinical practice.ConclusionOur findings will provide references for future clinical decision and guidance development.RegistrationINPLASY registration number: INPLASY202070024.

39 keywords...

hide…